Conservative Leverage (zero Debt)Zero debt provides durable financial flexibility for an R&D biotech, lowering bankruptcy risk and easing short-term cash flow pressure from interest obligations. This structural conservatism lengthens runway before financing and supports strategic R&D choices without leverage-driven constraints.

High Gross Margins On RevenueWhen commercial revenue occurred, gross margins were near full pass-through, indicating the company’s products or services can scale with relatively low incremental COGS. If clinical programs translate to recurring sales, strong gross margins improve leverage to profitability once fixed R&D and SG&A are controlled.

Platform In Immuno-oncology (CAR T, Oncolytic Viruses)A platform focus on CAR T and oncolytic viruses aligns with durable oncology secular growth and high unmet medical need. Platform technologies can create multiple product opportunities, enabling long-term upside from clinical success, partnerships, and potential licensing across tumor indications.

Bears Say

Persistent Operating And Net LossesConsistent operating and net losses plus negative operating/free cash flow reflect an inability to self-fund R&D and operations. Over time this necessitates recurring external capital, increases dilution risk, and can limit the company’s ability to advance multiple programs simultaneously without concessionary financing.

Revenue Volatility And 2025 Revenue LapseA collapse to zero revenue in 2025 signals weak commercial visibility and unreliable revenue streams. Structurally, this undermines forecasting, reduces confidence in commercialization capability, and increases dependence on financing or partnerships to sustain development and operations over the next 2–6 months and beyond.

Declining Equity CushionMaterial erosion of equity over multiple years reduces the balance sheet buffer against further losses, limiting solvency resilience. This structural decline increases the probability and potential size of future equity raises, diluting existing stakeholders and potentially constraining strategic options.

8E8 FAQ

What was Elicera Therapeutics AB’s price range in the past 12 months?

Elicera Therapeutics AB lowest stock price was €0.18 and its highest was €0.69 in the past 12 months.

What is Elicera Therapeutics AB’s market cap?

Elicera Therapeutics AB’s market cap is €24.03M.

When is Elicera Therapeutics AB’s upcoming earnings report date?

Elicera Therapeutics AB’s upcoming earnings report date is Apr 28, 2026 which is in 41 days.

How were Elicera Therapeutics AB’s earnings last quarter?

Elicera Therapeutics AB released its earnings results on Feb 13, 2026. The company reported -€0.013 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.013.

Is Elicera Therapeutics AB overvalued?

According to Wall Street analysts Elicera Therapeutics AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Elicera Therapeutics AB pay dividends?

Elicera Therapeutics AB does not currently pay dividends.

What is Elicera Therapeutics AB’s EPS estimate?

Elicera Therapeutics AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Elicera Therapeutics AB have?

Elicera Therapeutics AB has 48,535,545 shares outstanding.

What happened to Elicera Therapeutics AB’s price movement after its last earnings report?

Elicera Therapeutics AB reported an EPS of -€0.013 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.636%.

Which hedge fund is a major shareholder of Elicera Therapeutics AB?

Currently, no hedge funds are holding shares in DE:8E8

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Elicera Therapeutics AB

Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio of products in pipeline includes ELC-100, a Phase I/II drug candidate for neuroendocrine tumors indications; ELC-201, a preclinical drug candidate; ELC-301, a CAR T-cell therapy for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a preclinical drug candidate glioblastoma multiforme (brain tumor) indications. It also develops iTANK, a technology platform used to optimize the effect of all CAR T-cell therapies under the development and activate killer T-cells against cancer. The company was founded in 2014 and is based in Göteborg, Sweden.